Zevra Therapeutics Dividends
| ZVRA Stock | 9.50 0.07 0.74% |
As of November 29, 2024, Dividends Paid is expected to decline to about 277 K. In addition to that, Dividend Paid And Capex Coverage Ratio is expected to decline to -118.96. Zevra Therapeutics' past performance could be the main factor of why investors trade Zevra Therapeutics stock today. Investors should clearly understand every aspect of the Zevra Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Zevra Therapeutics' dividend schedule and payout information. Zevra Therapeutics dividends can also provide a clue to the current valuation of Zevra Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 291.6 K | 277 K | |
| Dividend Paid And Capex Coverage Ratio | (113.29) | (118.96) |
Zevra |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Zevra Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Zevra Therapeutics Dividends Paid Over Time
Today, most investors in Zevra Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zevra Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Zevra Therapeutics dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.